Reverse Transcriptase Inhibitors for Alzheimer's Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological diseases such as Alzheimer's lack effective methods to inhibit the progression of amyloid beta peptide accumulation and microglial cell death, which are key contributors to neuronal damage and cognitive decline.
Innovation Solution
Administration of a composition comprising reverse transcriptase inhibitors, specifically nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), which can be formulated for various routes of administration, including oral, injectable, and targeted drug delivery systems, to treat and inhibit the progression of neurological diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for neurological diseases are used, then existing therapies can be administered, but they fail to effectively inhibit amyloid beta peptide accumulation and microglial cell death
Solution Approach 1:
The patent identifies reverse transcriptase inhibitors as compounds that inadvertently prevent HIV replication while also providing neuroprotective effects. By converting the harmful action of HIV replication into a beneficial effect, these inhibitors reduce amyloid beta peptide accumulation and microglial cell death, thereby protecting neurons and improving cognitive function in Alzheimer's disease patients.
Solution Approach 2:
The patent explores changing the pharmacological parameters by using reverse transcriptase inhibitors at specific dosages and combinations. By adjusting these parameters, the treatment achieves effective inhibition of amyloid beta peptide accumulation and microglial cell death, transforming the disease progression trajectory from harmful to beneficial.
2Reliability
If reverse transcriptase inhibitors are administered to treat Alzheimer's disease, then amyloid beta peptide development and microglial cell death are reduced, but the mechanism was not originally designed for this purpose
Solution Approach 1:
The patent highlights the multi-functionality of reverse transcriptase inhibitors, which were originally developed for HIV treatment but also provide neuroprotective effects. These inhibitors simultaneously prevent HIV replication and reduce amyloid beta peptide accumulation and microglial cell death, making them universally applicable for both HIV treatment and Alzheimer's disease management.
Solution Approach 2:
The patent introduces reverse transcriptase inhibitors as intermediary compounds that mediate between HIV treatment and Alzheimer's disease treatment. These inhibitors serve as a bridge, providing neuroprotective effects while maintaining their primary function in preventing HIV replication, thus simplifying the overall treatment approach.
3Adaptability or versatility
If multiple neurological diseases are treated with the same composition, then treatment versatility is improved, but the complexity of treating different conditions increases
Solution Approach 1:
The patent demonstrates the universality of reverse transcriptase inhibitors by showing their effectiveness across multiple neurological diseases including Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. This multi-functionality allows a single composition to treat diverse diseases, reducing the need for multiple specialized treatments and simplifying the overall therapeutic approach.
Data Source
AI summary
Methods for treating and/or inhibiting progression of neurological diseases, conditions, and/or disorders. In some embodiments, the methods include administering to as subject in need thereof a composition that includes a reverse transcriptase inhibitor. Also provided are methods for inhibiting development of amyloid beta peptide (Aβ) in subjects, methods for inhibiting microglial cell death, and composition for use in the presently disclosed methods.